These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36999510)

  • 1. Molecular imaging of gliomas.
    Metz MC; Wiestler B
    Clin Neuropathol; 2023; 42(4):131-139. PubMed ID: 36999510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
    Patel SH; Poisson LM; Brat DJ; Zhou Y; Cooper L; Snuderl M; Thomas C; Franceschi AM; Griffith B; Flanders AE; Golfinos JG; Chi AS; Jain R
    Clin Cancer Res; 2017 Oct; 23(20):6078-6085. PubMed ID: 28751449
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas.
    Nishikawa T; Ohka F; Aoki K; Suzuki H; Motomura K; Yamaguchi J; Maeda S; Kibe Y; Shimizu H; Natsume A; Innan H; Saito R
    Brain Tumor Pathol; 2023 Apr; 40(2):85-92. PubMed ID: 36991274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
    Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
    Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.
    Kanazawa T; Minami Y; Takahashi H; Fujiwara H; Toda M; Jinzaki M; Yoshida K; Sasaki H
    Neurosurg Rev; 2020 Aug; 43(4):1211-1219. PubMed ID: 31402410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.